Multiple barriers may stop high-risk individuals from accessing an HIV drug that can reduce the subsequent risk of infection, according to a new University of Michigan study.
An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world.
African-Americans are still much more likely to be diagnosed with HIV than white Americans.
Understanding the evolution of a 400 million-year-old anti-viral protein that first emerged in marine life, is helping researchers get the upper-hand on human immunodeficiency virus (HIV).
By destroying the regulatory genes of the AIDS virus HIV-1 using the genome editing system CRISPR/Cas9, a Japanese research group has succeeded in blocking the production of HIV-1 by infected cells.
HIV patients on a single-tablet daily regimen had better treatment retention and viral suppression than patients taking multiple pills, in a study by a Michael E. DeBakey Veterans Affairs Medical Center researcher and his colleagues.
Anthony S. Fauci, MD, director, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) and Maureen M. Goodenow, PhD, director of the NIH Office of AIDS Research, have issued the following statement:
A stem cell is one with infinite possibilities. So, for decades, scientists have puzzled over how the cell chooses to keep being a stem cell and continue dividing, or specialize into a specific cell type, like a heart or brain cell.
A research team led by scientists at AIDS Institute and Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU) invents a universal antibody drug against HIV/AIDS.
NIH Clinical Trial to Track Outcomes of Kidney Transplantation from HIV-Positive Donors to HIV-Positive Recipients
The first large-scale clinical trial to study kidney transplantations between people with HIV has begun at clinical centers across the United States.